CITA Biomedical Licenses UROD Treatment to a Major Florida Medical Center.

Business Editors & Health/Medical Writers

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Sept. 4, 2001

CITA Biomedical Inc. (OTCBB:DTOX), a growing leader in the innovative treatment of addiction dependency, today announced that it has signed a license agreement with a major South Florida medical center.

The agreement enables the medical center to provide CITA's U.S. patented Ultra Rapid Opiate Detoxification (UROD(R)) treatment method to opiate-dependent patients.

"We are delighted that the UROD(R) treatment method will be available to the southeast United States," said Joseph Dunn, president and CEO of CITA Biomedical. "The UROD(R) treatment method has been successfully applied to detoxify thousands of patients worldwide, with more than 2,000 patients treated in the United States."

UROD(R) is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin and OxyContin -- within four to six hours with minimal withdrawal symptoms.

The treatment provides a safe and humane detoxification approach for patients, making it a far less painful recovery process than currently offered alternatives. This approach significantly enhances motivation for individuals who wish to overcome addiction.

CITA also offers a comprehensive, one-year continuing care program -- FIT(SM) (Flexible Intensity Treatment). After the UROD(R) procedure, the patient embarks on a six-month medication and ongoing therapy regimen. The aftercare medication works by blocking opiate receptors in the central nervous system, allowing for continued repair and regeneration.

Unlike alternative processes, the medication used in the FIT process is not a substitute for heroin or other opiates, and creates no further dependency. In fact, while on the aftercare medication, if a patient uses opiates again, the euphoric "high" is not experienced.

In addition to general therapy-related services, a key component of its continuing care program is www.CubeCentral.com. -- CITA's online community Web site. It was created to provide a host of products, support and services designed to aid addicts and recovering addicts, as well as family, friends and professionals, who may be affected by addiction and addiction recovery.

About CITA Biomedical Inc.

CITA Biomedical, with headquarters in Beverly Hills, focuses on the innovative treatment of addiction. The company holds a U.S. patent for its successful UROD(R) (Ultra Rapid Opiate Detoxification) treatment method. CITA grows its business through internal expansion and seeks compatible, competitive and complementing technologies and acquisitions to enhance its corporate portfolio.

CITA Biomedical has two operating divisions: CITA Americas Inc. and CubeCentral.com Inc. For more information, visit www.citabio.com.

Note to Editors: UROD is a registered trademark of CITA Biomedical Inc. FIT is a service mark of CITA Biomedical Inc.